{
    "nodes": [
        [
            "Cetuximab",
            "DRUG"
        ],
        [
            "Fluorouracil",
            "DRUG"
        ],
        [
            "4URU The crystal structure of H-Ras and SOS in complex with ligands",
            "PDB_STRUCTURE"
        ],
        [
            "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]",
            "PDB_STRUCTURE"
        ],
        [
            "Irinotecan",
            "DRUG"
        ],
        [
            "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide",
            "COMPOUND"
        ],
        [
            "Panitumumab",
            "DRUG"
        ],
        [
            "AZD 6244",
            "COMPOUND"
        ],
        [
            "KRAS",
            "GENE"
        ]
    ],
    "edges": [
        [
            [
                "KRAS",
                "Irinotecan"
            ],
            12.809579999999999,
            [
                [
                    "Victoria Chung, Jonathan D Mizrahi, Shubham Pant (2024). Novel Therapies for Pancreatic Cancer. JCO oncology practice, OP2400279. https://doi.org/10.1200/OP.24.00279 PMID: 39591547",
                    "39591547"
                ],
                [
                    "Juhi Mody, Mandana Kamgar (2024). Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. Case reports in oncology, 399-406. https://doi.org/10.1159/000536552 PMID: 38435447",
                    "38435447"
                ],
                [
                    "Sophie Laroche, Olivier Scatton, Frederic Charlotte, Jean-Baptiste Bachet, Chetana Lim, David Fuks, Claire Goumard (2024). Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases. Annals of surgical oncology, 4436-4444. https://doi.org/10.1245/s10434-024-15196-x PMID: 38549003",
                    "38549003"
                ],
                [
                    "Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang (2023). A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer. Cancer research and treatment. https://doi.org/10.4143/crt.2023.1117 PMID: 38062706",
                    "38062706"
                ],
                [
                    "Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamaguchi, Fumito Tamura, Hiroyuki Nagashima, Koshi Fujikawa, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama (2023). Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer. Frontiers in oncology, 1203296. https://doi.org/10.3389/fonc.2023.1203296 PMID: 37434969",
                    "37434969"
                ],
                [
                    "Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Araujo (2023). Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-023-00964-x PMID: 37608030",
                    "37608030"
                ],
                [
                    "Pilar García-Alfonso, Astrid Lièvre, Fotios Loupakis, Abir Tadmouri, Sadya Khan, Leticia Barcena, Sebastian Stintzing (2022). Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Critical reviews in oncology/hematology, 103646. https://doi.org/10.1016/j.critrevonc.2022.103646 PMID: 35344913",
                    "35344913"
                ],
                [
                    "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518",
                    "34431518"
                ],
                [
                    "Arata Nishimoto (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World journal of gastroenterology, 3637-3643. https://doi.org/10.3748/wjg.v28.i28.3637 PMID: 36161054",
                    "36161054"
                ],
                [
                    "Min Shi, Hong Yuan, Jun Ji, Shouwei Zhang, Qingyuan Li, Yawei Chen, Xiaoli Gong, Zhenggang Zhu, Jun Zhang (2022). Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic advances in medical oncology, 17588359211070643. https://doi.org/10.1177/17588359211070643 PMID: 35096147",
                    "35096147"
                ]
            ]
        ],
        [
            [
                "KRAS",
                "Cetuximab"
            ],
            20.27984,
            [
                [
                    "John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura, Kanwal Raghav, Salvatore Siena, Josep Tabernero, Eric Van Cutsem, Takayuki Yoshino, Jorge Ramos, Xuesong Guan, Thierry Andre (2024). MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future oncology (London, England), 1-9. https://doi.org/10.1080/14796694.2024.2441101 PMID: 39723627",
                    "39723627"
                ],
                [
                    "John D Mason, Ewan Marks, Shih-Jung Fan, Kristie McCormick, Clive Wilson, Adrian L Harris, Freddie C Hamdy, Chris Cunningham, Deborah C I Goberdhan (2024). Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer. Journal of extracellular vesicles, e12465. https://doi.org/10.1002/jev2.12465 PMID: 38887984",
                    "38887984"
                ],
                [
                    "Saikat Chowdhury, Ria Gupta, Joshua Millstein, Kangyu Lin, Valsala Haridas, Mohammad A Zeineddine, Christine Parseghian, Heinz-Josef Lenz, Scott Kopetz, John Paul Shen (2023). Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO precision oncology, e2200422. https://doi.org/10.1200/PO.22.00422 PMID: 37487150",
                    "37487150"
                ],
                [
                    "Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez, María J de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The oncologist, 230-238. https://doi.org/10.1093/oncolo/oyad007 PMID: 36811382",
                    "36811382"
                ],
                [
                    "Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Araujo (2023). Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer. https://doi.org/10.1007/s12029-023-00964-x PMID: 37608030",
                    "37608030"
                ],
                [
                    "Pilar García-Alfonso, Astrid Lièvre, Fotios Loupakis, Abir Tadmouri, Sadya Khan, Leticia Barcena, Sebastian Stintzing (2022). Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Critical reviews in oncology/hematology, 103646. https://doi.org/10.1016/j.critrevonc.2022.103646 PMID: 35344913",
                    "35344913"
                ],
                [
                    "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518",
                    "34431518"
                ],
                [
                    "Wai-Hung Leung, Jing-Wen Shih, Jian-Syun Chen, Ntlotlang Mokgautsi, Po-Li Wei, Yan-Jiun Huang (2022). Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling. Biomedicines. https://doi.org/10.3390/biomedicines10020377 PMID: 35203586",
                    "35203586"
                ],
                [
                    "Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, Kensei Yamaguchi, Hiroyuki Uetake, Takayuki Yoshino, Satoshi Morita, Keiichi Takahashi, Michiaki Unno, Yasuhiro Shimada, Kei Muro, Nobuhisa Matsuhashi, Masaki Mori, Hideo Baba, Mitsuo Shimada, Yoshihiro Mise, Yoshikuni Kawaguchi, Tatsuo Kagimura, Kiyoshi Ishigure, Akio Saiura, Kenichi Sugihara, Norihiro Kokudo (2022). A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbeck's archives of surgery, 1345-1356. https://doi.org/10.1007/s00423-022-02434-7 PMID: 35211831",
                    "35211831"
                ],
                [
                    "Glaucia Maria de Mendonça Fernandes, Vilson Serafim Junior, Ana Lívia Silva Galbiatti-Dias, Leticia Antunes Muniz Ferreira, Márcia Maria Urbanin Castanhole-Nunes, Rosa Sayoko Kawasaki-Oyama, José Victor Maniglia, Erika Cristina Pavarino, Eny Maria Goloni-Bertollo (2022). Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells. American journal of cancer research, 4196-4210. PMID: 36225637",
                    "36225637"
                ]
            ]
        ],
        [
            [
                "KRAS",
                "AZD 6244"
            ],
            2.221586,
            [
                [
                    "Margarita Dionysiou, Stavriani C Makri, Shivani Ahlawat, Melike Guryildirim, Kristin W Barañano, Mari L Groves, Pedram Argani, Christine A Pratilas (2024). Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient. Frontiers in neurology, 1466946. https://doi.org/10.3389/fneur.2024.1466946 PMID: 39385823",
                    "39385823"
                ],
                [
                    "Jianan Qiao, Shuhui Liu, Yanfeng Huang, Xiang Zhu, Chenyang Xue, Yan Wang, Hui Xiong, Jing Yao (2024). Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment. Journal of colloid and interface science, 477-490. https://doi.org/10.1016/j.jcis.2024.02.141 PMID: 38429120",
                    "38429120"
                ],
                [
                    "Mark Jackson, Niousha Ahmari, Jianqiang Wu, Tilat A Rizvi, Elizabeth Fugate, Mi-Ok Kim, Eva Dombi, Heribert Arnhof, Guido Boehmelt, Matthias J Düchs, Clive J Long, Udo Maier, Francesca Trapani, Marco H Hofmann, Nancy Ratner (2023). Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics, 106-116. https://doi.org/10.1124/jpet.122.001431 PMID: 36849412",
                    "36849412"
                ],
                [
                    "Baojun Ren, Yan Geng, Shuxiang Chen, Zhuowei Gao, Kehong Zheng, Yong Yang, Qimei Luo, Jing Feng, Zhentao Luo, Yongle Ju, Zonghai Huang (2023). Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines. Experimental and therapeutic medicine, 243. https://doi.org/10.3892/etm.2023.11942 PMID: 37153900",
                    "37153900"
                ],
                [
                    "Wenfang Zheng, Zhiyi Yang, Ping Song, Yingchao Sun, Pan Liu, Lei Yue, Kaiqi Lv, Xinjie Wang, Yuqin Shen, Jianmin Si, Xue Zhang, Yuehai Ke, Hongqiang Cheng, Weiling Hu (2023). SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity. Cancer letters, 216029. https://doi.org/10.1016/j.canlet.2022.216029 PMID: 36493900",
                    "36493900"
                ],
                [
                    "Yahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang, Hongqi Tian (2023). Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. Frontiers in pharmacology, 1271268. https://doi.org/10.3389/fphar.2023.1271268 PMID: 37808191",
                    "37808191"
                ],
                [
                    "Wei-Wei Wang, Wei-Qi Wang, Shan-Shan Wang, Lei Pan (2022). The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis. Annals of translational medicine, 593. https://doi.org/10.21037/atm-22-1849 PMID: 35722363",
                    "35722363"
                ],
                [
                    "Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam (2022). Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific reports, 1248. https://doi.org/10.1038/s41598-022-05193-z PMID: 35075200",
                    "35075200"
                ],
                [
                    "Emilie M J van Brummelen, Sanne Huijberts, Carla van Herpen, Ingrid Desar, Frans Opdam, Robin van Geel, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin Huitema, Jos Beijnen, Rene Bernards, Jan Schellens (2021). Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist, 290-e545. https://doi.org/10.1002/onco.13631 PMID: 33296125",
                    "33296125"
                ],
                [
                    "Francesca Fanini, Erika Bandini, Meropi Plousiou, Silvia Carloni, Petra Wise, Paolo Neviani, Mariam Murtadha, Flavia Foca, Francesco Fabbri, Ivan Vannini, Muller Fabbri (2021). MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. International journal of molecular sciences. https://doi.org/10.3390/ijms222413357 PMID: 34948154",
                    "34948154"
                ]
            ]
        ],
        [
            [
                "KRAS",
                "Panitumumab"
            ],
            11.008924,
            [
                [
                    "Manuel Valladares-Ayerbes, Maria José Safont, Encarnación González Flores, Pilar García-Alfonso, Enrique Aranda, Ana-Maria López Muñoz, Esther Falcó Ferrer, Luís Cirera Nogueras, Nuria Rodríguez-Salas, Jorge Aparicio, Marta Llanos Muñoz, Paola Patricia Pimentel Cáceres, Oscar Alfredo Castillo Trujillo, Rosario Vidal Tocino, Mercedes Salgado Fernández, Antonieta Salud-Salvia, Bartomeu Massuti Sureda, Rocio Garcia-Carbonero, Maria Ángeles Vicente Conesa, Ariadna Lloansí Vila,   (2024). Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2640-2651. https://doi.org/10.1007/s12094-024-03487-4 PMID: 38642257",
                    "38642257"
                ],
                [
                    "Gozde Kavgaci, Omer Dizdar, Suayib Yalcin (2024). Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. Anti-cancer drugs, 459-461. https://doi.org/10.1097/CAD.0000000000001587 PMID: 38451823",
                    "38451823"
                ],
                [
                    "Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Ikuo Mori, Kazunori Yamanaka, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Riu Yamashita, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino (2024). Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nature medicine, 730-739. https://doi.org/10.1038/s41591-023-02791-w PMID: 38347302",
                    "38347302"
                ],
                [
                    "Simon Haefliger, Katharina Marston, Ilaria Alborelli, Edouard-Jean Stauffer, Mathias Gugger, Philip M Jermann, Sylvia Hoeller, Luigi Tornillo, Luigi M Terracciano, Michel Bihl, Matthias S Matter (2023). Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics. Pathobiology : journal of immunopathology, molecular and cellular biology, 166-175. https://doi.org/10.1159/000526117 PMID: 36202073",
                    "36202073"
                ],
                [
                    "Ahmet Rencuzogullari, Atil Bisgin, Kivilcim Eren Erdogan, Serdar Gumus, Orcun Yalav, Ibrahim Boga, Ozge Sonmezler, Ismail Cem Eray (2023). Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel. Annali italiani di chirurgia, 605-611. PMID: 38131395",
                    "38131395"
                ],
                [
                    "Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang (2022). Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis. Expert review of anticancer therapy, 1333-1347. https://doi.org/10.1080/14737140.2022.2147512 PMID: 36374121",
                    "36374121"
                ],
                [
                    "Anyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, Lena E Friberg, Dirk Jan A R Moes (2022). Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance. Scientific reports, 4206. https://doi.org/10.1038/s41598-022-08012-7 PMID: 35273301",
                    "35273301"
                ],
                [
                    "Yifei Sun, Xuming He, Jianhua Hu (2022). AN OMNIBUS TEST FOR DETECTION OF SUBGROUP TREATMENT EFFECTS VIA DATA PARTITIONING. The annals of applied statistics, 2266-2278. https://doi.org/10.1214/21-AOAS1589 PMID: 37521002",
                    "37521002"
                ],
                [
                    "Huu Thinh Nguyen, Trieu Vu Nguyen, Van-Anh Nguyen Hoang, Duc Huy Tran, Ngoc An Le Trinh, Minh Triet Le, Tuan-Anh Nguyen Tran, Thanh Huyen Pham, Thi Cuc Dinh, Tien Sy Nguyen, Ky Cuong Nguyen The, Hoa Mai, Minh Tuan Chu, Dinh Hoang Pham, Xuan Chi Nguyen, Thien My Ngo Ha, Duy Sinh Nguyen, Du Quyen Nguyen, Y-Thanh Lu, Thanh Thuy Do Thi, Dinh Kiet Truong, Quynh Tho Nguyen, Hoai-Nghia Nguyen, Hoa Giang, Lan N Tu (2022). Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. Frontiers in oncology, 1069296. https://doi.org/10.3389/fonc.2022.1069296 PMID: 36578946",
                    "36578946"
                ],
                [
                    "Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Ding Wang, Ashwin R Sama, Fanny Piette, Katherine L Pogue-Geile, Rim S Kim, Patrick G Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F Kiesel, Jan H Beumer, Norman Wolmark, Peter C Lucas, Carmen J Allegra, Ashok Srinivasan (2021). Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 1612-1622. https://doi.org/10.1158/1078-0432.CCR-20-1831 PMID: 33203645",
                    "33203645"
                ]
            ]
        ],
        [
            [
                "4URU The crystal structure of H-Ras and SOS in complex with ligands",
                "KRAS"
            ],
            7.036307399999999
        ],
        [
            [
                "KRAS",
                "Fluorouracil"
            ],
            9.655294,
            [
                [
                    "Tasvi Daya, Andrea Breytenbach, Liang Gu, Mandeep Kaur (2024). Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies. Biochimica et biophysica acta. Molecular and cell biology of lipids, 159578. https://doi.org/10.1016/j.bbalip.2024.159578 PMID: 39542394",
                    "39542394"
                ],
                [
                    "Victoria Chung, Jonathan D Mizrahi, Shubham Pant (2024). Novel Therapies for Pancreatic Cancer. JCO oncology practice, OP2400279. https://doi.org/10.1200/OP.24.00279 PMID: 39591547",
                    "39591547"
                ],
                [
                    "Juhi Mody, Mandana Kamgar (2024). Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. Case reports in oncology, 399-406. https://doi.org/10.1159/000536552 PMID: 38435447",
                    "38435447"
                ],
                [
                    "Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang (2023). A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer. Cancer research and treatment. https://doi.org/10.4143/crt.2023.1117 PMID: 38062706",
                    "38062706"
                ],
                [
                    "Sora Kang, Myung-Won Lee, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Deog-Yeon Jo, Jung Sun Kim, Jung Hye Kwon, Ji-Yeon Kim, Kyung-Ha Lee, Hyewon Ryu (2023). Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status. Journal of cancer research and clinical oncology, 7819-7829. https://doi.org/10.1007/s00432-023-04720-3 PMID: 37031435",
                    "37031435"
                ],
                [
                    "Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Höffkes, Markus Moehler, Alena Britta Gesenhues, Sebastian Theurich, Marlies Michl, Dominik P Modest, Hana Algül, Sebastian Stintzing, Volker Heinemann, Julian W Holch (2022). Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). International journal of cancer, 112-123. https://doi.org/10.1002/ijc.33775 PMID: 34431518",
                    "34431518"
                ],
                [
                    "Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, Kensei Yamaguchi, Hiroyuki Uetake, Takayuki Yoshino, Satoshi Morita, Keiichi Takahashi, Michiaki Unno, Yasuhiro Shimada, Kei Muro, Nobuhisa Matsuhashi, Masaki Mori, Hideo Baba, Mitsuo Shimada, Yoshihiro Mise, Yoshikuni Kawaguchi, Tatsuo Kagimura, Kiyoshi Ishigure, Akio Saiura, Kenichi Sugihara, Norihiro Kokudo (2022). A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbeck's archives of surgery, 1345-1356. https://doi.org/10.1007/s00423-022-02434-7 PMID: 35211831",
                    "35211831"
                ],
                [
                    "Arata Nishimoto (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World journal of gastroenterology, 3637-3643. https://doi.org/10.3748/wjg.v28.i28.3637 PMID: 36161054",
                    "36161054"
                ],
                [
                    "Min Shi, Hong Yuan, Jun Ji, Shouwei Zhang, Qingyuan Li, Yawei Chen, Xiaoli Gong, Zhenggang Zhu, Jun Zhang (2022). Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic advances in medical oncology, 17588359211070643. https://doi.org/10.1177/17588359211070643 PMID: 35096147",
                    "35096147"
                ],
                [
                    "Y Sunakawa, H Satake, J Usher, Y Jaimes, Y Miyamoto, M Nakamura, M Kataoka, M Shiozawa, A Takagane, T Terazawa, T Watanabe, K Ishiguro, C Tanaka, M Takeuchi, M Fujii, K Danenberg, P V Danenberg, H-J Lenz, T Sekikawa, W Ichikawa (2022). Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO open, 100512. https://doi.org/10.1016/j.esmoop.2022.100512 PMID: 35688061",
                    "35688061"
                ]
            ]
        ],
        [
            [
                "5DTM Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]",
                "4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide"
            ],
            7.036307399999999
        ]
    ]
}